Search - tctmd.com

Displaying 901 - 920 of 1058

Sort: Relevancy | Date

Two-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents in De Novo Coronary Artery Lesions

Presentation ACC 2012

Two-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents in De Novo Coronary Artery Lesions

Presenter: Gregg Stone

March 28, 2012

News Conference News ACC 2012

Two Studies Highlight Safety, Efficacy of Biodegradable Polymer SES

March 26, 2012

News Conference News ACC 2012

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

March 26, 2012

News Daily News

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

March 25, 2012

News Daily News

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

March 25, 2012

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

March 24, 2012

Biodegradable Polymer Drug-Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention

Presentation ACC 2012

Biodegradable Polymer Drug-Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention

Presenter: Robert A. Byrne

March 24, 2012

News Conference News ACC 2012

Anti-inflammatory Lowers In-Stent Late Loss After BMS Implantation

March 24, 2012

Controversy 1: Current Drug-Eluting Stents Are Not Only More Effective But Are Safer Than Bare Metal Stents and Should Be Used in more than 90% of (Stented) Patients

Presentation PCI Outcomes 2012

Controversy 1: Current Drug-Eluting Stents Are Not Only More Effective But Are Safer Than Bare Metal Stents and Should Be Used in more than 90% of (Stented) Patients

Presenter: Gregg W. Stone

March 23, 2012

News Daily News

El Celecoxib Aumenta la Eficacia de los SLF a un determinado Coste Clínico

March 15, 2012

News Daily News

Celecoxib Enhances DES Efficacy, But at Clinical Cost

March 15, 2012

News Daily News

TCTMD’s Top 10 Most Popular News Stories From 2011

March 08, 2012

News Daily News

Los 10 Artículos Más Populares de TCTMD de 2011

March 08, 2012

News Daily News

Study Finds No ‘Obesity Paradox’ in DES-Treated Patients

March 06, 2012

News Daily News

Stent Thrombosis Risk Lower with Xience vs. First-Generation DES

Yael L. Maxwell

March 06, 2012

News Daily News

It’s DESTINY: DES Superior to BMS for Below-the-Knee Lesions

March 06, 2012

News Daily News

Ensayo DESTINY: los SLF son Superiores a los SMD en lesiones por debajo de la rodilla

March 06, 2012

News Daily News

El Riesgo de Trombosis del Stent es Menor con Xience que con SLF de 1ª Generación

Yael L. Maxwell

March 06, 2012

News Daily News

El Estudio no Halla “Paradoja de la Obesidad” alguna en Pacientes Tratados con SLF

March 06, 2012

News Daily News

Statins Reduce Late Restenosis After SES Implantation

March 05, 2012

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.